Published by Josh White on 24th June 2024
(Sharecast News) - GSK announced on Monday that it has received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for 'Omjjara', or momelotinib, as a treatment for myelofibrosis.
URL: http://www.digitallook.com/dl/news/story/34381270/...